CASE REPORT
Remission in lupus nephritis – report of three cases
Online publication date: 2013-03-03
Reumatologia 2013;51(1):85-88
KEYWORDS
ABSTRACT
In this paper we present the course of lupus nephritis (LN) of three patients who were treated aggressively from the onset of the disease with glucocorticoid (GC), cyclophosphamide (CYC) and then mycophenolate mofetil (MMF). In two patients class IV of LN was confirmed in the renal biopsy and secondary antiphospholipid syndrome (APS) was diagnosed. Applying the treatment regimen based on CYC in the induction of remission and then MMF as the maintenance therapy led to the remission of kidney symptoms, but both stages of treatment were correlated with infectious complications.
Applying aggressive treatment from the onset of the disease while considering simultaneously the risk of possible complications gives the chance to achieve complete remission of LN.
Applying aggressive treatment from the onset of the disease while considering simultaneously the risk of possible complications gives the chance to achieve complete remission of LN.
REFERENCES (10)
1.
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686.
2.
Ruiz-Irastorza G, Espinosa G, Frutos MA, et al. Diagnosis and treatment of lupus nephritis. Nefrologia 2012; 32 Suppl. 1: 1-35. .
3.
Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revised. J Am Soc Nephrol 2004; 15: 241-250.
5.
Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112. .
6.
Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010; 21: 2028-2035. .
7.
Majdan M. Zespół antyfosfolipidowy a choroby nerek. Pol Merk Lek 2010; 167: 341-344.
8.
Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus in clinical trials. Arthritis Rheum 2006; 54: 421-432.
9.
Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012; 64: 797-808.
10.
Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2010; 22: 504-509.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
